Bone News and Research

RSS

CONMED Linvatec produces the smallest Biocomposite Interference screw for fixation of ACL and PCL grafts

CONMED Corporation's CONMED Linvatec arthroscopy unit today announced the release of new sizes of its Matryx™ Biocomposite Interference Screw. These new screws represent the latest advance in biocomposite material technology that allows CONMED Linvatec to produce the smallest Biocomposite Interference screw available on the market today for primary fixation of ACL and PCL grafts.

17 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Phase II clinical study to evaluate Nanocort commenced

Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments.

17 Nov 2009

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS).

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Bullseye Anatomic Cruciate Reconstruction System released

CONMED Corporation's CONMED Linvatec arthroscopy unit today announced the release of the Bullseye™ Anatomic Cruciate Reconstruction System, a novel guide system for anatomic cruciate ligament (ACL and PCL) reconstructions of the knee.

16 Nov 2009

UT physicians treat Iraqi girl with myasthenia gravis

Plagued by a growing weakness that left her unable to walk, talk and even take a normal breath, 11-year-old Iraqi Aram Ali was a shell of the bright little girl she used to be.

16 Nov 2009

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone.

16 Nov 2009

Two units of UCB reduce risk of leukemia from returning, shows new study

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.

16 Nov 2009

Misonix inks a three-year distribution agreement with Xenith in Dubai

Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year distribution agreement with Xenith, LLC, based in Dubai, UAE, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider.

13 Nov 2009

Improved method of chest closure may set new standard of care for open-heart surgery

An innovative method is being used to repair the breastbone after it is intentionally broken to provide access to the heart during open-heart surgery. The technique uses a state-of-the-art adhesive that rapidly bonds to bone and accelerates the recovery process.

13 Nov 2009

$Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not$

Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not

New results from a survey of 1,122 post-menopausal women in Asia found that nearly half (48.5 percent) were not aware whether or not they had osteoporosis despite being hospitalized with a fragility fracture.

13 Nov 2009

Bone News and Research

CONMED Linvatec produces the smallest Biocomposite Interference screw for fixation of ACL and PCL grafts

Cancer pain drug market to be $3.7 billion in 2018

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Genentech submits sBLAs to the FDA for Avastin

Phase II clinical study to evaluate Nanocort commenced

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Onyx Pharmaceuticals acquires Proteolix

Myeloma UK launches innovative clinical trial network

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces Phase 3 trial results of Genasense

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Bullseye Anatomic Cruciate Reconstruction System released

UT physicians treat Iraqi girl with myasthenia gravis

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Two units of UCB reduce risk of leukemia from returning, shows new study

Misonix inks a three-year distribution agreement with Xenith in Dubai

Improved method of chest closure may set new standard of care for open-heart surgery

Post-menopausal women in Asia hospitalized with fragility fracture are not aware whether they had osteoporosis or not

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News